Research programme: CNS disorders therapeutics - Chronos Therapeutics

Drug Profile

Research programme: CNS disorders therapeutics - Chronos Therapeutics

Latest Information Update: 25 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shire
  • Developer Chronos Therapeutics
  • Class
  • Mechanism of Action Central nervous system modulators; Orexin receptor type 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Fatigue; Impulse control disorders; Post-traumatic stress disorders

Most Recent Events

  • 25 Jul 2016 Chronos Therapeutics acquires CNS disorders therapeutics from Shire
  • 20 Jul 2016 Preclinical trials in Post-traumatic stress disorder, Impulse control disorders, and Fatigue in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top